Combined androgen blockade with bicalutamide for advanced prostate cancer: Long-term follow-up of a phase 3, double-blind, randomized study for survival Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan has released some very significant survival data about a previously reported, double-blind, randomized, multicenter phase 3 trial. This trial compared combined androgen blockade [...]
There was just a release of some of the data from the on-going review sipuleucel-T, or Provenge, in men with early stage recurrent prostate cancer who have a rising serum prostate specific antigen (PSA) level, but who have not yet developed metastatic prostate cancer. The data wes presented by Oregon Health & Realm University Cancer [...]
There is some good news on the horizon, or at least we are setting up for the possibility of some future good news. Coming off of the recent news about the very successful phase II trial of CB7630 (abiraterone acetate), Cougar Biotechnology, Inc. has reached agreement with the FDA under a special protocol assessment (SPA) [...]
Malecare presents to you a chance to make $125 for yourselves and $100 for Malecare. We usually do not participate in these market research headhunts, but, this one seems ok, brief in time and, it actually will help Malecare. We are currently trying to raise money to improve our website, malecare.com . Schlesinger Associates, a [...]
Scott Goodwin has been a guest writer on this blog. He has been sharing his experiences and feelings as he continues his journey on chemotherapy. Scott is not doing as well as we all had hoped. His final paragraph says "When does the time come when a man will stop all treatments and try to [...]